目的探讨扎鲁司特 ( zafirlukast,商品名 :安可来 )在轻、中度哮喘患者中的临床疗效及其安全性。方法哮喘患者口服扎鲁司特2 0 mg,每天 2次 ,持续 4周。结果哮喘患者口服扎鲁司特后日间和夜间症状计分、夜间憋醒次数、无症状天数、吸入β2 受体激动剂用量及肺通气功能指标 FEV1 、PEFam、PEFpm均有显著改善。不良反应 2例 ( 3.8% ) ,症状轻微。结论扎鲁司特对轻、中度哮喘具有缓解症状和改善肺功能的作用 ,具有副作用少 ,耐受性好的优点 Objective To investigate the clinical efficacy and safety of zafirlukast (trade name: Aroclor) in patients with mild to moderate asthma. Methods Patients with asthma were given oral zafirlukast 20 mg twice daily for 4 weeks. Results After oral administration of zaludox in patients with asthma, symptom scores, nighttime arousal, asymptomatic days, inhaled β2 agonist dosage and FEV1, PEFam and PEFpm were significantly improved. Adverse reactions in 2 cases (3.8%), minor symptoms. Conclusions Zafirlukast has the effect of relieving symptoms and improving pulmonary function in mild and moderate asthma with few side effects and good tolerability